Prevalence of CKD in T2DM by race
| Prevalence of CKD by race | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Non-Hispanic white | Non-Hispanic black | Mexican-American | Other Hispanic | Other race—including multiracial | ||||||
| eGFR determined by CKD-EPI | N | % (95% CI) | N | % (95% CI) | N | % (95% CI) | N | % (95% CI) | N | % (95% CI) |
| No CKD | 390 | 61.3 (57.9 to 64.7) | 291 | 56.5 (51.2 to 61.9) | 201 | 56.5 (49.7 to 63.3) | 147 | 69.0 (65.0 to 73.1) | 93 | 62.9 (55.5 to 70.3) |
| CKD all stages | 336 | 38.7 (35.3 to 42.1) | 255 | 43.5 (38.1 to 48.8) | 155 | 43.5 (36.7 to 50.3) | 78 | 31.0 (26.9 to 35.0) | 60 | 37.1 (29.7 to 44.5) |
| Stage 1 (eGFR≥90 and UACR≥30 mg/g) | 44 | 5.9 (4.2 to 7.6) | 58 | 11.4 (7.9 to 14.9) | 63 | 22.5 (17.4 to 27.6) | 21 | 8.0 (4.9 to 11.2) | 15 | 6.0 (2.9 to 9.0) |
| Stage 2 (eGFR 60–89 and UACR≥30 mg/g) | 82 | 9.3 (6.7 to 12.0) | 56 | 9.2 (6.2 to 12.2) | 38 | 9.5 (6.2 to 12.8) | 27 | 9.7 (6.5 to 13.0) | 18 | 16.9 (8.2 to 25.7) |
| Stage 3a (eGFR 45–59) | 113 | 13.6 (11.1 to 16.1) | 88 | 13.8 (11.0 to 16.7) | 26 | 5.0 (3.2 to 6.8) | 17 | 7.3 (3.6 to 11.0) | 13 | 6.4 (1.4 to 11.4) |
| Stage 3b (eGFR 30–44) | 71 | 6.9 (5.1 to 8.7) | 24 | 4.0 (2.2 to 5.8) | 18 | 3.9 (1.1 to 6.6) | 11 | 5.2 (2.2 to 8.3) | 9 | 4.8 (0.9 to 8.7) |
| Stage 4 (eGFR 15–29) | 25 | 2.9 (1.6 to 4.2) | 15 | 2.5 (1.2 to 3.8) | 5 | 1.6 (0.2 to 2.9) | * | 0.0 (0.0 to 0.0) | 3 | 2.3 (0.0 to 5.1) |
| Stage 5 (eGFR <15) | * | 0.1 (0.0 to 0.2) | 14 | 2.6 (0.9 to 4.3) | 5 | 1.1 (0.0 to 2.2) | * | 0.7 (0.0 to 1.6) | * | 0.7 (0.0 to 1.7) |
| Total | 726 | 100 | 546 | 100 | 356 | 100 | 225 | 100 | 153 | 100 |
*Cell frequency suppressed when count <3 to avoid potential imprecision of estimates.
CKD, chronic kidney disease; CKD-EPI, the Chronic Kidney Disease Epidemiology Collaboration equation; eGFR, estimated glomerular filtration rate (mL/min/1.72 m2); T2DM, type 2 diabetes mellitus; UACR, urinary albumin:creatinine ratio (mg/g).